Previous 10 | Next 10 |
Sarissa does not understand why the Alkermes independent directors refuse to add Sarissa representatives to the board Sarissa believes the addition of its representatives to the Alkermes board can unlock shareholder value and allow Alkermes to achieve its true potential Sarissa ...
Alkermes Issues Letter to Shareholders Highlighting Skills and Experience of Refreshed Board of Directors PR Newswire Sarissa's Proposed Candidates Would Not Bring New Skills to the Board Recommends Shareholders Vote "FOR" Alkermes' Director Nominees on Company's WHI...
Sarissa Capital Management LP (“Sarissa”) today issued a presentation detailing the need for shareholder representation on the board of Alkermes (NASDAQ: ALKS) accessible at the link below: Presentation: https://upgradealkermes.com/pr060923 For additional information...
Alkermes Publishes Investor Presentation Detailing Company's Transformation and Value Creation PR Newswire Strategic, Operational and Governance Enhancements Have Driven Strong Stock Price Performance and TSR Outperformance in Comparison to Peers Reiterates Board's Bel...
NORTHAMPTON, MA / ACCESSWIRE / June 7, 2023 / Alkermes In 2021, the Alkermes Inspiration Grants program funded nonprofit programs providing support for patient communities in the areas of addiction , serious mental illness and cancer . Watch this video to hear grantees' perspectives about t...
2023-06-06 07:25:55 ET Alkermes plc ( NASDAQ: ALKS ) increased its full-year outlook ahead of Street forecasts on Tuesday to account for a final financial award received from Johnson & Johnson ( NYSE: JNJ ) unit Janssen in connection with an arbitration related to a lice...
Alkermes Announces Final Award in Janssen Pharmaceutica Arbitration and Provides Updated Financial Expectations PR Newswire — Company Raises 2023 Revenue and GAAP Net Income Expectations by Approximately $425 Million — — Conference Call Schedul...
Sarissa believes its nominees have experience and skills that the current board lacks Sarissa does not understand why the Alkermes independent directors refuse to add any Sarissa representatives to the board Sarissa Capital today released the following letter to shareholders of ...
2023-06-01 16:16:07 ET Alkermes ( NASDAQ: ALKS ) has chosen Caroline Loew as CEO designate of Mural Oncology, the company said Thursday. Mural Oncology is the new independent public company to be established upon the planned separation of the company'...
Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive Officer Designate of Mural Oncology plc PR Newswire — Dr. Loew to Assume New Leadership Role Upon Completion of the Planned Separation of Alkermes' Oncology Business — — Planned Separati...
News, Short Squeeze, Breakout and More Instantly...
Alkermes to Report Second Quarter Financial Results on July 24, 2024 PR Newswire DUBLIN , July 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Wednesday, ...
2024-06-29 16:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-19 17:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...